Mantell Associates

We have reached our next milestone of 85,000 followers on LinkedIn! Thank you to all our clients, candidates and wider network who have followed our journey since 2019. We look forward to continuing to connect with you all, providing industry insights and news as well as incredible opportunities within the Pharmaceutical and Life Science space. #followers #milestone #recruitment

Visiox Pharmaceuticals Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines. Together they aim to emerge as a leader in the eye care sector with a strong portfolio of ophthalmic medicines. Read more: https://lnkd.in/edw4XXCH #ophthalmic #eyecare #ophthalmicmedicines

A huge thank you to Tom Bryan as he celebrates one year at Mantell Associates! Tom joined the MA team in August 2023 to set up and lead our UK Contract division. Over the past year he has built out our contract book, signed a record number of new clients across the US and Europe, expanded his team, and has been a great addition to the London office! Congratulations on your one year anniversary Tom! #workanniversary #team #thankyou

ST PHARM, a technology-driven RNA CDMO, and Quantoom Biosciences, a specialised RNA technology platform developer, have teamed up to accelerate the development and manufacturing of RNA-based vaccines and therapeutics. Read more: https://lnkd.in/eyncw3Qb #RNA #vaccines #CDMO

FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organisation (CDMO), has opened a microbial fermentation manufacturing facility in Billingham, which triples microbial production throughput. Read more: https://lnkd.in/e86fsx8c #microbialfermentation #CDMO #microbialproduction

Thomas White discusses the dominance of CRDMOs compared to CDMOs. This article explores the rise of CRDMOs, their advantages over traditional CDMOs, and the strategic value of incorporating research and development (R&D) into the outsourcing model. Read more: https://lnkd.in/eEKB77bp #researchanddevelopment #CRDMO #research

Our CEO Alessandro Mantell leading from the front! A great testimonial from one of our longest-standing partners in the CDMO space. "Top notch service provided by Alessandro and Mantell Associates. I have worked with them to rapidly build multiple commercial organizations." #testimonialtuesday #clienttestimonial #recommendation

Bridge Biotherapeutics, Inc., a clinical-stage biotechnology company, has formed a strategic alliance with HitGen Inc., a leading Chinese drug discovery platform company, to accelerate the development of novel anticancer drug candidates. The collaboration builds upon the success of initial hit finding and identification work utilising HitGen Inc.'s DNA-encoded library (DEL) technology. Read more: https://lnkd.in/esAZgCVF #drugdiscovery #anticancer #cancertherapeutics

eXmoor Pharma, a provider of cell and gene therapy manufacturing services, has achieved a significant milestone with the receipt of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This authorization allows eXmoor to manufacture good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials. Read more: https://lnkd.in/ec-aqu8x #celltherapy #RNAResearch #FDAApproval #PharmaCompliance

Novartis has announced the formation of Borealis Biosciences, Inc., an independent, discovery-stage biotechnology company focused on developing next-generation xRNA-based medicines for kidney diseases. The new company is a result of a partnership between Novartis and Versant Ventures, and is based in Vancouver, Canada. Read more: https://lnkd.in/eF7ADYyw #kidneydisease #advancedtherapies #xRNA